STAIR: An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)

IRB/UVA Tracking #
18632
Principal Investigator
Barrett Matthew,
Contact First Name

Stephanie

Contact Last Name

Lowenhaupt

Contact Email
Contact Phone
Official Trial Title
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)
Study Description

University of Virginia- Department of Neurology is currently looking for people with Huntington’s Disease (HD) exhibiting irritability and aggression for a research study conducted by the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). Dr. Michael Brownstein (Azevan Pharmaceuticals) and Dr. Steven Hersch (Massachusetts General Hospital) are leading this national study. The National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH) and Azevan Pharmaceuticals are supporting the trial.
The purpose of the research study is to find out if SRX246 is a safe and effective drug for people with HD. The study will enroll 108 people with HD, exhibiting symptoms of irritability and aggression. Participants have a 2 out of 3 chance of receiving study drug, SRX246, and 1 out of 3 chance of receiving placebo.
Participants must be at least 18 years old and have a diagnosis of Huntington’s Disease, symptoms of irritability and aggression, and a study partner who is willing to participate in the study.

This study is actively enrolling participants. To learn more information, please visit http://www.neuronext.org or contact Stephanie Lowenhaupt RN CCRC at the University of Virginia by phone 434-982-6961 or email sal3q@virginia.edu

Compensation

No Compensation